Hormonal
Hot flashes (vasomotor symptoms) are a major contributor to sleep disturbances during the menopausal transition, with HF-associated wake time significantly contributing to overall wakefulness after sleep onset (WASO).
If you are experiencing sleep issues during menopause, recognize that hot flashes are a primary driver of fragmented sleep. This is a physiological response to hormonal changes, not just 'aging'. Treating the hot flashes (via hormonal or non-hormonal options) often improves sleep quality, which is crucial for long-term health.
A major contributor to sleep complaints in the context of the menopausal transition is HFs, and many, although not all, HFs are linked with polysomnographic-defined awakenings, with HF-associated wake time contributing significantly to overall wakefulness after sleep onset.
Why this rating
Supported by both self-report and polysomnographic (PSG) evidence, including longitudinal studies.
Source
Sleep problems during the menopausal transition: prevalence, impact, and management challenges
Fiona C. Baker et al. · Nature and Science of Sleep · 2018
DOI 10.2147/nss.s125807
More from this paper
- Menopausal stage (early/late transition, postmenopause) is associated with increased odds of self-reported sleep difficulties, particularly frequent awakenings, independent of age.Good
- Surgical menopause (bilateral oophorectomy) is associated with more severe sleep disturbances and higher prevalence of sleep difficulty compared to natural menopause, largely due to more severe hot flashes.Good
- Polysomnographic (PSG) measures do not consistently show sleep architecture changes linked directly to menopausal stage, despite strong self-report of sleep difficulties.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →